Therefore, TAA-specific CD8+ T cell responses could reduce the recurrence of HCC suggesting that immunotherapy to induce TAA-specific CTLs by such means as peptide vaccines might be an effective clinical application in HCC patients after local therapy [113]. This evidence concerns the gene CD8A and hepatocellular carcinoma.